Inventaire - your friends and communities are your best library

The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer

author

Imanol Arozarena

published in: Frontiers in Cell and Developmental Biology

date of publication: 2016-04-27

language: English

main subject: skin cancer

Cites articles 97

Date

Title

Authors

2016-03

A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation

Pilar Garin-Chesa
2016-03-01

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy

Michael P Smith, Holly Brunton, Imanol Arozarena, Mitchell P Levesque, Zachary A. Cooper, Claudia Wellbrock, Jennifer Wargo, Reinhard Dummer
2015-09-02

BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition

Elisa de Stanchina
2015-05-31

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Filippo de Braud, Jean-Jacques Grob, Caroline Robert, Daniil Stroyakovskiy, Ana Arance, Virginia Ferraresi, Igor N. Bondarenko, Jochen Utikal, Georgina V. Long, Dirk Schadendorf, Keith Flaherty, Evgeny V Levchenko, Antoni Ribas, Axel Hauschild
2015-05-13

Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression

Bartosz Chmielowski, Grant McArthur, Antoni Ribas, Keith Flaherty, Patrick Hwu
2015-04-01

Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling

Erik Sahai, Michiyuki Matsuda
2015-04-17

Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy

Claudia Wellbrock, Imanol Arozarena
2015-03-25

Therapy-induced tumour secretomes promote resistance and tumour progression

Anna C Obenauf, Yilong Zou, Hubing Shi, Thomas Wiesner, Joan Massagué Solé
2015-01-23

BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth

Meenhard Herlyn, Clemens Krepler, Tara C Gangadhar, Giorgos Karakousis
2014-11-13

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

Claus Garbe, Antoni Ribas, Brigitte Dréno, Daniil Stroyakovskiy, Grant McArthur, Michele Maio, Paolo Antonio Ascierto, James Larkin, Mario Mandala, Luc Thomas, Luis de la Cruz-Merino, Caroline Dutriaux, Ilsung Chang, Gabriella Liszkay
2014-04-03

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

Federica Di Nicolantonio, Alberto Bardelli, Alexander Eggermont, Caroline Robert, Chong Sun, Stephan Vagner, René Bernards, Christian U Blank, Sebastijan Hobor, Davide Zecchin
2014-12-15

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

Willy Hugo, Colin R. Goding, Ultan McDermott, Thomas Graeber, Antoni Ribas, Daniel Peeper, Christian U Blank
2014-12-11

Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma

Berta Sanchez-Laorden, Lawrence C. Davies, Steven Whittaker, Neil O Carragher, Caroline J Springer, Alfonso Zambon, Paul Lorigan, Louise Johnson, Margaret Frame
2014-10-01

The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα

Michael P Smith, Berta Sanchez-Laorden, Holly Brunton, Helen L Young, Zachary A. Cooper, Claudia Wellbrock, Jennifer Wargo
2014-06-11

Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53

Berta Sanchez-Laorden, Simon J. Furney, Richard Marais
2014-05-22

Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors

Natalie Louise Stephenson, Zoe C Edwards, Richard Marais
2014-04-25

A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors

Jill P. Mesirov, Keith Flaherty, Levi A Garraway, David E. Fisher, Pablo Tamayo, William C Hahn, Omar O Abudayyeh, David J Konieczkowski, Cory M Johannessen, Ravid Straussman, Jennifer Wargo
2014-12-10

A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors

Josep Tabernero Caturla, Philippe L. Bedard, Filip Janku
2014-12-29

Temperature-sensitive splicing of mitfa by an intron mutation in zebrafish

E. Elizabeth Patton
2014-11-25

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
2013-03

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

Dirk Schadendorf, Axel Hauschild, Reinhard Dummer, Paolo Antonio Ascierto, Christian U Blank
2013-03

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition

Jean-Philippe Theurillat, Dirk Schadendorf, Levi A Garraway, David E Root, Glenn S Cowley
2013-02-14

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

Reinhard Dummer
2013-11-21

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

Bartosz Chmielowski, Antoni Ribas, Georgina V. Long, Richard F. Kefford, Xiangju Kong, Jeffrey A Sosman, Hubing Shi, Aayoung Hong, Richard C Koya, Gatien Moriceau, Willy Hugo, Thinle Chodon
2013-11-21

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma

Steven Whittaker, Kristian Cibulskis, Gad Getz, Amaro Taylor-Weiner, Antje Sucker, Selma Ugurel, Dirk Schadendorf, Stacey Gabriel, Levi A Garraway, Eran Hodis, Deborah N Farlow, Aaron McKenna
2013-11-01

Tumor adaptation and resistance to RAF inhibitors
2013-10-01

Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma
2013-04-24

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors

Rumin Zhang
2013-04-21

IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors

Pawel K Mazur, Julien Sage
2013-02-27

BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition

Satoru Yokoyama, Elena Balestreire Hawryluk, Dave S. Hoon, Jun S Song, Robert S. Langer, Jr., David E. Fisher, Donald Morton, Jennifer Wargo
2013-07-05

A conditional zebrafish MITF mutation reveals MITF levels are critical for melanoma promotion vs. regression in vivo

Ian J. Jackson, E. Elizabeth Patton
2012-02-23

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Bartosz Chmielowski, Antoni Ribas, Igor Puzanov, Grant McArthur, Richard F. Kefford, Keith Flaherty

Article - wd:Q26747247

Welcome to Inventaire

the library of your friends and communities

learn more